359 related items for PubMed ID: 22869678
21. [Efficacy of glucocorticoids combined with immunoglobulin in initial treatment of Kawasaki disease: a Meta analysis].
Li J, Wang BL, Feng RB, Li GD.
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Jun; 18(6):527-33. PubMed ID: 27324542
[Abstract] [Full Text] [Related]
22. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, Takahashi K, Okada S, Wakiguchi H, Moriwake T, Uchida M, Ohbuchi N, Iwai T, Hasegawa M, Ichihara K, Yashiro M, Makino N, Nakamura Y, Ohga S.
Int J Cardiol; 2016 Jul 01; 214():209-15. PubMed ID: 27070994
[Abstract] [Full Text] [Related]
23. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T, Murakami S, Matsumoto K, Matsuda A.
Pediatr Rheumatol Online J; 2020 Oct 06; 18(1):76. PubMed ID: 33023630
[Abstract] [Full Text] [Related]
24. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 06; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
25. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
Pediatr Cardiol; 2015 Aug 06; 36(6):1166-72. PubMed ID: 25812827
[Abstract] [Full Text] [Related]
26. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
[Abstract] [Full Text] [Related]
27. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
[Abstract] [Full Text] [Related]
28. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
Brogan P, Levin M.
Evid Based Med; 2013 Dec 15; 18(6):217-8. PubMed ID: 23564929
[No Abstract] [Full Text] [Related]
29. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.
Pediatr Infect Dis J; 2009 Jun 15; 28(6):498-502. PubMed ID: 19504733
[Abstract] [Full Text] [Related]
30. Kawasaki disease: a comprehensive review of treatment options.
Patel RM, Shulman ST.
J Clin Pharm Ther; 2015 Dec 15; 40(6):620-5. PubMed ID: 26547265
[Abstract] [Full Text] [Related]
31. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 15; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
32. [Steroid pulse therapy].
Miura M.
Nihon Rinsho; 2014 Sep 15; 72(9):1631-5. PubMed ID: 25518414
[Abstract] [Full Text] [Related]
33. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
Nihon Rinsho; 2008 Feb 15; 66(2):338-42. PubMed ID: 18265457
[Abstract] [Full Text] [Related]
34. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
J Rheumatol; 2012 Apr 15; 39(4):864-7. PubMed ID: 22337241
[Abstract] [Full Text] [Related]
35. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
[Abstract] [Full Text] [Related]
36. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
Pediatr Neonatol; 2014 Oct 27; 55(5):387-92. PubMed ID: 24636168
[Abstract] [Full Text] [Related]
37. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 27; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
38. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
Pediatr Int; 2001 Jun 27; 43(3):211-7. PubMed ID: 11380911
[Abstract] [Full Text] [Related]
39. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb 27; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
40. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
Zheng X, Li J, Yue P, Liu L, Li J, Zhou K, Hua Y, Li Y.
PLoS One; 2021 Feb 27; 16(3):e0248812. PubMed ID: 33764989
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
